Kyverna therapeutics provides business update and reports fourth quarter and full year 2024 financial results

Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis aligned with the u.s. food and drug administration (fda) on a registrational phase 2 trial design for ongoing kysa-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1h 2026; biologics license application (bla) filing targeted for 2026   clinical data in myasthenia gravis and lupus nephritis expected in 2h 2025   strong balance sheet extends cash runway into 2027 through key clinical and regulatory catalysts emeryville, calif. , march 27, 2025 /prnewswire/ -- kyverna therapeutics, inc. (nasdaq: kytx), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the full year 2024.
KYTX Ratings Summary
KYTX Quant Ranking